In many countries, ripretinib can be used as a fourth-line treatment and avapritinib has been approved for PDGFRA exon 18-mutated GIST, while pimitespib is now approved as fourth-line treatment for GIST in Japan. This evidence concerns the gene PDGFRA and gastrointestinal stromal tumor.